| Primary | Change in the Young Mania Rating Scale (YMRS) Total Score From Baseline to Final Assessment (Day 43) | The YMRS total score ranges from 0 to 60 where higher scores indicate more severe mania, thus, a negative change (or decrease) from baseline indicates a reduction (or improvement) in manic symptoms. Total score ≤12 indicates remission (13-19=minimal symptoms; 20-25=mild mania, 26-37=moderate mania, 38-60=severe mania). | 173/176 is modified intent to treat analysis set. The reason why is different from 173/183 is that there is 7 patients excluded from the analysis (1 patient who did not take study drug and 6 patients who did not have post treatment YMRS scores). | Posted | Nov 2011 | Least Squares Mean | Standard Error | Scores on a scale | | Change in YMRS total score from baseline to Day 43. | | | | ID | Title | Description |
|---|
| OG000 | Lithium+Quetiapine XR | Lithium 600 to 1800 mg/day+quetiapine XR 400 to 800 mg/day | | OG001 | Placebo+Quetiapine XR | Placebo+quetiapine XR 400 to 800 mg/day |
| | | Title | Denominators | Categories |
|---|
| | | Title | Measurements |
|---|
| - OG000-22.8± 0.706(0.706 to )
- OG001-20.1± 0.711(0.711 to )
|
|
| |
| Secondary | The Number of Patients With Clinically Significant Response. | The number of patients with clinically significant response (defined as ≥50% reduction from baseline to Day 43 in the YMRS total score) was calculated. The YMRS total score ranges from 0 to 60 where higher scores indicate more severe mania, thus, a negative change (or 50% reduction) from baseline indicates a reduction (or improvement) in manic symptoms. | 173/176 is modified intent to treat analysis set. The reason why is different from 173/183 is that there is 7 patients excluded from the analysis (1 patient who did not take study drug and 6 patients who did not have post treatment YMRS scores). | Posted | Nov 2011 | Number | | Participants | | 43 days (from baseline to Day 43) | | | | ID | Title | Description |
|---|
| OG000 | Lithium+Quetiapine XR | Lithium 600 to 1800 mg/day+quetiapine XR 400 to 800 mg/day | | OG001 | Placebo+Quetiapine XR | Placebo+quetiapine XR 400 to 800 mg/day |
| |
| Secondary | Remission | The number of patients with clinically significant remission (defined as YMRS total score ≤12) from Days 8 to 43) was calculated. The Young Mania Rating Scale total score ranges from 0 to 60 where higher scores indicate more severe mania, thus, a negative change (or 50% reduction) from baseline indicates a reduction (or improvement) in manic symptoms. Total score ≤12 indicates remission (13-19=minimal symptoms; 20-25=mild mania, 26-37=moderate mania, 38-60=severe mania). | 173/176 is modified intent to treat analysis set. The reason why is different from 173/183 is that there is 7 patients excluded from the analysis (1 patient who did not take study drug and 6 patients who did not have post treatment YMRS scores). | Posted | Nov 2011 | Number | | Participants | | Days 8 to 43 | | | | ID | Title | Description |
|---|
| OG000 | Lithium+Quetiapine XR | Lithium 600 to 1800 mg/day+quetiapine XR 400 to 800 mg/day | | OG001 | Placebo+Quetiapine XR | Placebo+quetiapine XR 400 to 800 mg/day |
| |
| Secondary | Change From Baseline to Day 43 in CGI-BP-S (Clinical Global Impressions for Bipolar Disorder-Severity of Illness) | The CGI-BP-S scale rates the severity of the patient's illness at the time of assessment and is scored from 1 to 7 (1=normal, not ill to 7=very severely ill). Higher CGI-BP-S scores indicate greater illness severity. | 173/176 is modified intent to treat analysis set. The reason why is different from 173/183 is that there is 7 patients excluded from the analysis (1 patient who did not take study drug and 6 patients who did not have post treatment YMRS scores). | Posted | Nov 2011 | Least Squares Mean | Standard Error | Scores on a scale | | Change from baseline to Day 43. | | | | ID | Title | Description |
|---|
| OG000 | Lithium+Quetiapine XR | Lithium 600 to 1800 mg/day+quetiapine XR 400 to 800 mg/day | | OG001 | Placebo+Quetiapine XR | Placebo+quetiapine XR 400 to 800 mg/day |
| |
| Secondary | Change From Baseline to Day 43 in CGI-BP-C (Clinical Global Impressions for Bipolar Disorder-Change From Preceding Phase) | The CGI-BP-C scale rates how much the patient's illness has improved or worsened compared to the phase immediately preceding treatment and is scored on a scale from 1 to 8 (1=very much improved to 7=very much worse; 8=not applicable). A missing score will be used when a scale scored as 8 (not applicable). CGI-BP-C scores >4 indicate worsening, while scores <4 indicate improvement. | 173/176 is modified intent to treat analysis set. The reason why is different from 173/183 is that there is 7 patients excluded from the analysis (1 patient who did not take study drug and 6 patients who did not have post treatment YMRS scores). | Posted | Nov 2011 | Least Squares Mean | Standard Error | Scores on a scale | | Change from baseline to Day 43 | | | | ID | Title | Description |
|---|
| OG000 | Lithium+Quetiapine XR | Lithium 600 to 1800 mg/day+quetiapine XR 400 to 800 mg/day | | OG001 | Placebo+Quetiapine XR | Placebo+quetiapine XR 400 to 800 mg/day |
| |
| Secondary | Improvement of Overall Bipolar Illness | The number of patients with a CGI-BP-C of "Much" or "Very much" improved in overall bipolar illness assessment at Day 43 was calculated. The CGI-BP-C scale rates how much the patient's illness has improved or worsened compared to the phase immediately preceding treatment and is scored on a scale from 1 to 8 (1=very much improved to 7=very much worse; 8=not applicable). A missing score will be used when a scale scored as 8 (not applicable). CGI-BP-C scores >4 indicate worsening, while scores <4 indicate improvement. | 173/176 is modified intent to treat analysis set. The reason why is different from 173/183 is that there is 7 patients excluded from the analysis (1 patient who did not take study drug and 6 patients who did not have post treatment YMRS scores). | Posted | Nov 2011 | Number | | Participants | | Day 43. | | | | ID | Title | Description |
|---|
| OG000 | Lithium+Quetiapine XR | Lithium 600 to 1800 mg/day+quetiapine XR 400 to 800 mg/day | | OG001 | Placebo+Quetiapine XR | Placebo+quetiapine XR 400 to 800 mg/day |
| |
| Secondary | Change From Baseline to Day 43 in Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score | The MADRS is a 10-item scale that evaluates depressive symptoms. Each MADRS item is rated on a 0 to 6 scale. Higher MADRS scores indicate higher levels of depressive symptoms. | | Posted | Nov 2011 | Least Squares Mean | Standard Error | Scores on a scale | | Change from baseline to Day 43. | | | | ID | Title | Description |
|---|
| OG000 | Lithium+Quetiapine XR | Lithium 600 to 1800 mg/day+quetiapine XR 400 to 800 mg/day | | OG001 | Placebo+Quetiapine XR | Placebo+quetiapine XR 400 to 800 mg/day |
| |
| Secondary | Change From Baseline to Day 43 in Positive and Negative Syndrome Scale (PANSS) Total Score | The PANSS is a 30-item scale designed to assess various symptoms of schizophrenia and are rated on a 7-point scale that ranges from 1 (absent) to 7 (extreme psychopathology). The PANSS total score is the sum of all 30 individual-item scores and ranges from 30 to 210.A negative change (or decrease) from baseline indicates a reduction (or improvement) in symptoms. | 173/176 is modified intent to treat analysis set. The reason why is different from 173/183 is that there is 7 patients excluded from the analysis (1 patient who did not take study drug and 6 patients who did not have post treatment YMRS scores). | Posted | Nov 2011 | Least Squares Mean | Standard Error | Scores on a scale | | Change from baseline to Day 43 | | | | ID | Title | Description |
|---|
| OG000 | Lithium+Quetiapine XR | Lithium 600 to 1800 mg/day+quetiapine XR 400 to 800 mg/day | | OG001 | Placebo+Quetiapine XR | Placebo+quetiapine XR 400 to 800 mg/day |
| |
| Secondary | Change From Baseline to Day 43 in PANSS Activation Subscale Score | The PANSS is a 30-item scale designed to assess various symptoms of schizophrenia and are rated on a 7-point scale that ranges from 1 (absent) to 7 (extreme psychopathology). The PANSS activation subscale score for effect on agitation and aggression is the sum of 6 PANSS individual items (ie, hostility, poor impulse control, excitement, uncooperativeness, poor rapport and tension) and ranges from 6 to 42. A negative change (or decrease) from baseline indicates a reduction (or improvement) in symptoms. | 173/176 is modified intent to treat analysis set. The reason why is different from 173/183 is that there is 7 patients excluded from the analysis (1 patient who did not take study drug and 6 patients who did not have post treatment YMRS scores). | Posted | Nov 2011 | Least Squares Mean | Standard Error | Scores on a scale | | Change from baseline to Day 43 | | | | ID | Title | Description |
|---|
| OG000 | Lithium+Quetiapine XR | Lithium 600 to 1800 mg/day+quetiapine XR 400 to 800 mg/day | | OG001 | Placebo+Quetiapine XR | Placebo+quetiapine XR 400 to 800 mg/day |
| |
| Secondary | Change From Baseline to Day 43 in PANSS Positive Subscale Score | The PANSS is a 30-item scale designed to assess various symptoms of schizophrenia and are rated on a 7-point scale that ranges from 1 (absent) to 7 (extreme psychopathology). The PANSS positive subscale score is the sum of the 7 positive item scores (ie, delusions, conceptual disorganization, hallucinatory behavior, excitement, grandiosity, suspiciousness/persecution and hostility) and ranges from 7 to 49. A negative change (or decrease) from baseline indicates a reduction (or improvement) in symptoms. | 173/176 is modified intent to treat analysis set. The reason why is different from 173/183 is that there is 7 patients excluded from the analysis (1 patient who did not take study drug and 6 patients who did not have post treatment YMRS scores). | Posted | Nov 2011 | Least Squares Mean | Standard Error | Scores on a scale | | Change from baseline to Day 43 | | | | ID | Title | Description |
|---|
| OG000 | Lithium+Quetiapine XR | Lithium 600 to 1800 mg/day+quetiapine XR 400 to 800 mg/day | | OG001 | Placebo+Quetiapine XR | Placebo+quetiapine XR 400 to 800 mg/day |
| |
| Secondary | Change From Baseline to Day 43 in Each YMRS Item Score No. 1 | The YMRS assesses severity of mania in bipolar disorder. It rates 4 core items from 0 to 8 (0=normal); the other 7 items are rated from 0 to 4 (0=normal). This analysis is for Item 1 (Elevated mood) which ranges from 0 to 4 where higher scores indicate more severe symptoms, thus, a negative change (or decrease) from baseline indicates a reduction (or improvement) in symptoms. | 173/176 is modified intent to treat analysis set. The reason why is different from 173/183 is that there is 7 patients excluded from the analysis (1 patient who did not take study drug and 6 patients who did not have post treatment YMRS scores). | Posted | Nov 2011 | Least Squares Mean | Standard Error | Scores on a scale | | Change from baseline to Day 43 | | | | ID | Title | Description |
|---|
| OG000 | Lithium+Quetiapine XR | Lithium 600 to 1800 mg/day+quetiapine XR 400 to 800 mg/day | | OG001 | Placebo+Quetiapine XR | Placebo+quetiapine XR 400 to 800 mg/day |
| |
| Secondary | Change From Baseline to Day 43 in Each YMRS Item Score No. 2 | The YMRS assesses severity of mania in bipolar disorder. It rates 4 core items from 0 to 8 (0=normal); the other 7 items are rated from 0 to 4 (0=normal). This analysis is for Item 2 (increased motor activity-energy) which ranges from 0 to 4 where higher scores indicate more severe symptoms, thus, a negative change (or decrease) from baseline indicates a reduction (or improvement) in symptoms. | 173/176 is modified intent to treat analysis set. The reason why is different from 173/183 is that there is 7 patients excluded from the analysis (1 patient who did not take study drug and 6 patients who did not have post treatment YMRS scores). | Posted | Nov 2011 | Least Squares Mean | Standard Error | Scores on a scale | | Change from baseline to Day 43 | | | | ID | Title | Description |
|---|
| OG000 | Lithium+Quetiapine XR | Lithium 600 to 1800 mg/day+quetiapine XR 400 to 800 mg/day | | OG001 | Placebo+Quetiapine XR | Placebo+quetiapine XR 400 to 800 mg/day |
| |
| Secondary | Change From Baseline to Day 43 in Each YMRS Item Score No. 3 | The YMRS assesses severity of mania in bipolar disorder. It rates 4 core items from 0 to 8 (0=normal); the other 7 items are rated from 0 to 4 (0=normal). This analysis is for Item 3 (sexual interest) which ranges from 0 to 4 where higher scores indicate more severe symptoms, thus, a negative change (or decrease) from baseline indicates a reduction (or improvement) in symptoms. | 173/176 is modified intent to treat analysis set. The reason why is different from 173/183 is that there is 7 patients excluded from the analysis (1 patient who did not take study drug and 6 patients who did not have post treatment YMRS scores). | Posted | Nov 2011 | Least Squares Mean | Standard Error | Scores on a scale | | Change from baseline to Day 43 | | | | ID | Title | Description |
|---|
| OG000 | Lithium+Quetiapine XR | Lithium 600 to 1800 mg/day+quetiapine XR 400 to 800 mg/day | | OG001 | Placebo+Quetiapine XR | Placebo+quetiapine XR 400 to 800 mg/day |
| |
| Secondary | Change From Baseline to Day 43 in Each YMRS Item Score No. 4 | The YMRS assesses severity of mania in bipolar disorder. It rates 4 core items from 0 to 8 (0=normal); the other 7 items are rated from 0 to 4 (0=normal). This analysis is for Item 4 (sleep) which ranges from 0 to 4 where higher scores indicate more severe symptoms, thus, a negative change (or decrease) from baseline indicates a reduction (or improvement) in symptoms. | | Posted | Nov 2011 | Least Squares Mean | Standard Error | Scores on a scale | | Change from baseline to Day 43 | | | | ID | Title | Description |
|---|
| OG000 | Lithium+Quetiapine XR | Lithium 600 to 1800 mg/day+quetiapine XR 400 to 800 mg/day | | OG001 | Placebo+Quetiapine XR | Placebo+quetiapine XR 400 to 800 mg/day |
| |
| Secondary | Change From Baseline to Day 43 in Each YMRS Item Score No. 5 | The YMRS assesses severity of mania in bipolar disorder. It rates 4 core items from 0 to 8 (0=normal); the other 7 items are rated from 0 to 4 (0=normal). This analysis is for Item 5 (Irritability) which ranges from 0 to 8 where higher scores indicate more severe symptoms, thus, a negative change (or decrease) from baseline indicates a reduction (or improvement) in symptoms. | 173/176 is modified intent to treat analysis set. The reason why is different from 173/183 is that there is 7 patients excluded from the analysis (1 patient who did not take study drug and 6 patients who did not have post treatment YMRS scores). | Posted | Nov 2011 | Least Squares Mean | Standard Error | Scores on a scale | | Change from baseline to Day 43 | | | | ID | Title | Description |
|---|
| OG000 | Lithium+Quetiapine XR | Lithium 600 to 1800 mg/day+quetiapine XR 400 to 800 mg/day | | OG001 | Placebo+Quetiapine XR | Placebo+quetiapine XR 400 to 800 mg/day |
| |
| Secondary | Change From Baseline to Day 43 in Each YMRS Item Score No. 6 | The YMRS assesses severity of mania in bipolar disorder. It rates 4 core items from 0 to 8 (0=normal); the other 7 items are rated from 0 to 4 (0=normal). This analysis is for Item 6 (speech-rate and amount) which ranges from 0 to 8 where higher scores indicate more severe symptoms, thus, a negative change (or decrease) from baseline indicates a reduction (or improvement) in symptoms. | 173/176 is modified intent to treat analysis set. The reason why is different from 173/183 is that there is 7 patients excluded from the analysis (1 patient who did not take study drug and 6 patients who did not have post treatment YMRS scores). | Posted | Nov 2011 | Least Squares Mean | Standard Error | Scores on a scale | | Change from baseline to Day 43 | | | | ID | Title | Description |
|---|
| OG000 | Lithium+Quetiapine XR | Lithium 600 to 1800 mg/day+quetiapine XR 400 to 800 mg/day | | OG001 | Placebo+Quetiapine XR | Placebo+quetiapine XR 400 to 800 mg/day |
| |
| Secondary | Change From Baseline to Day 43 in Each YMRS Item Score No. 7 | The YMRS assesses severity of mania in bipolar disorder. It rates 4 core items from 0 to 8 (0=normal); the other 7 items are rated from 0 to 4. This analysis is for Item 7 (language-thought disorder) which ranges from 0 to 4 where higher scores indicate more severe symptoms, thus, a negative change (or decrease) from baseline indicates a reduction (or improvement) in symptoms. | 173/176 is modified intent to treat analysis set. The reason why is different from 173/183 is that there is 7 patients excluded from the analysis (1 patient who did not take study drug and 6 patients who did not have post treatment YMRS scores). | Posted | Nov 2011 | Least Squares Mean | Standard Error | Scores on a scale | | Change from baseline to Day 43 | | | | ID | Title | Description |
|---|
| OG000 | Lithium+Quetiapine XR | Lithium 600 to 1800 mg/day+quetiapine XR 400 to 800 mg/day | | OG001 | Placebo+Quetiapine XR | Placebo+quetiapine XR 400 to 800 mg/day |
| |
| Secondary | Change From Baseline to Day 43 in Each YMRS Item Score No. 8 | The YMRS assesses severity of mania in bipolar disorder. It rates 4 core items from 0 to 8 (0=normal); the other 7 items are rated from 0 to 4. This analysis is for Item 8 (content) which ranges from 0 to 8 where higher scores indicate more severe symptoms, thus, a negative change (or decrease) from baseline indicates a reduction (or improvement) in symptoms. | 173/176 is modified intent to treat analysis set. The reason why is different from 173/183 is that there is 7 patients excluded from the analysis (1 patient who did not take study drug and 6 patients who did not have post treatment YMRS scores). | Posted | Nov 2011 | Least Squares Mean | Standard Error | Scores on a scale | | Change from baseline to Day 43 | | | | ID | Title | Description |
|---|
| OG000 | Lithium+Quetiapine XR | Lithium 600 to 1800 mg/day+quetiapine XR 400 to 800 mg/day | | OG001 | Placebo+Quetiapine XR | Placebo+quetiapine XR 400 to 800 mg/day |
| |
| Secondary | Change From Baseline to Day 43 in Each YMRS Item Score No. 9 | The YMRS assesses severity of mania in bipolar disorder. It rates 4 core items from 0 to 8 (0=normal); the other 7 items are rated from 0 to 4. . This analysis is for Item 9 (disruptive-aggressive behavior) which ranges from 0 to 8 where higher scores indicate more severe symptoms, thus, a negative change (or decrease) from baseline indicates a reduction (or improvement) in symptoms. | 173/176 is modified intent to treat analysis set. The reason why is different from 173/183 is that there is 7 patients excluded from the analysis (1 patient who did not take study drug and 6 patients who did not have post treatment YMRS scores). | Posted | Nov 2011 | Least Squares Mean | Standard Error | Scores on a scale | | Change from baseline to Day 43 | | | | ID | Title | Description |
|---|
| OG000 | Lithium+Quetiapine XR | Lithium 600 to 1800 mg/day+quetiapine XR 400 to 800 mg/day | | OG001 | Placebo+Quetiapine XR | Placebo+quetiapine XR 400 to 800 mg/day |
| |
| Secondary | Change From Baseline to Day 43 in Each YMRS Item Score No. 10 | The YMRS assesses severity of mania in bipolar disorder. It rates 4 core items from 0 to 8 (0=normal); the other 7 items are rated from 0 to 4. This analysis is for Item 10 (appearance) which ranges from 0 to 4 where higher scores indicate more severe symptoms, thus, a negative change (or decrease) from baseline indicates a reduction (or improvement) in symptoms. | 173/176 is modified intent to treat analysis set. The reason why is different from 173/183 is that there is 7 patients excluded from the analysis (1 patient who did not take study drug and 6 patients who did not have post treatment YMRS scores). | Posted | Nov 2011 | Least Squares Mean | Standard Error | Scores on a scale | | Change from baseline to Day 43 | | | | ID | Title | Description |
|---|
| OG000 | Lithium+Quetiapine XR | Lithium 600 to 1800 mg/day+quetiapine XR 400 to 800 mg/day | | OG001 | Placebo+Quetiapine XR | Placebo+quetiapine XR 400 to 800 mg/day |
| |
| Secondary | Change From Baseline to Day 43 in Each YMRS Item Score No. 11 | The YMRS assesses severity of mania in bipolar disorder. It rates 4 core items from 0 to 8 (0=normal); the other 7 items are rated from 0 to 4. This analysis is for Item 11 (insight) which ranges from 0 to 4 where higher scores indicate more severe symptoms, thus, a negative change (or decrease) from baseline indicates a reduction (or improvement) in symptoms. | 173/176 is modified intent to treat analysis set. The reason why is different from 173/183 is that there is 7 patients excluded from the analysis (1 patient who did not take study drug and 6 patients who did not have post treatment YMRS scores). | Posted | Nov 2011 | Least Squares Mean | Standard Error | Scores on a scale | | Change from baseline to Day 43 | | | | ID | Title | Description |
|---|
| OG000 | Lithium+Quetiapine XR | Lithium 600 to 1800 mg/day+quetiapine XR 400 to 800 mg/day | | OG001 | Placebo+Quetiapine XR | Placebo+quetiapine XR 400 to 800 mg/day |
| |